Investigating ZNF410 to increase fetal hemoglobin levels
Targeting ZNF410 for HbF reactivation
['FUNDING_R01'] · BOSTON CHILDREN'S HOSPITAL · NIH-11051852
This study is looking at a protein called ZNF410 to see if it can help boost fetal hemoglobin levels in people with sickle cell disease and β-thalassemia, with the hope of finding new treatments that make living with these conditions easier.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON CHILDREN'S HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11051852 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how ZNF410, a protein that regulates fetal hemoglobin (HbF), can be targeted to increase HbF levels in patients with hemoglobin disorders like sickle cell disease and β-thalassemia. By exploring the mechanisms of ZNF410's action and its role in blood cell formation, the research aims to develop new pharmacotherapies that could effectively treat these conditions. The approach includes studying the interactions of ZNF410 with other proteins and testing targeted therapies that could enhance HbF production, potentially offering a new treatment avenue for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with sickle cell disease or β-thalassemia who are 21 years or older.
Not a fit: Patients with hemoglobin disorders who are under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the management of hemoglobin disorders, reducing reliance on supportive therapies.
How similar studies have performed: Other research has shown promise in targeting similar pathways for increasing fetal hemoglobin, suggesting that this approach could be effective.
Where this research is happening
BOSTON, UNITED STATES
- BOSTON CHILDREN'S HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BAUER, DANIEL EVAN — BOSTON CHILDREN'S HOSPITAL
- Study coordinator: BAUER, DANIEL EVAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.